"Neo-Adjuvant Treatment with the CDK4,6 inhibitor Palbociclib in HER2-positive and ER-positive breast cancer: effect on Ki67 and apoptosis before, during and after treatment "

Trial Profile

"Neo-Adjuvant Treatment with the CDK4,6 inhibitor Palbociclib in HER2-positive and ER-positive breast cancer: effect on Ki67 and apoptosis before, during and after treatment "

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2016

At a glance

  • Drugs Palbociclib (Primary) ; Fulvestrant; Pertuzumab; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Apr 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 20 Aug 2015 Planned End Date changed from 22 Jul 2016 to 1 Sep 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top